{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:13:14Z","timestamp":1793423594831,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10557-026-07882-7","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:21:45Z","timestamp":1777098105000},"page":"1993-2008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Mechanisms Underlying the Comorbidity of Type 2 Diabetes Mellitus and Coronary Artery Disease: from Insulin Resistance and Inflammation to Endothelial Dysfunction and Therapeutic Implications"],"prefix":"10.1007","volume":"40","author":[{"given":"Min","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirun","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"7882_CR1","doi-asserted-by":"publisher","first-page":"1359255","DOI":"10.3389\/fendo.2024.1359255","volume":"15","author":"DR Yang","year":"2024","unstructured":"Yang DR, et al. Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications. Front Endocrinol (Lausanne). 2024;15:1359255.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"7882_CR2","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47 Suppl 1:S179\u2013S218.","DOI":"10.2337\/dc24-S010"},{"issue":"6","key":"7882_CR3","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.2337\/db16-0152","volume":"65","author":"GL King","year":"2016","unstructured":"King GL, Park K, Li Q. Selective Insulin Resistance and the Development of Cardiovascular Diseases in Diabetes: The 2015 Edwin Bierman Award Lecture. Diabetes. 2016;65(6):1462\u201371.","journal-title":"Diabetes"},{"issue":"3","key":"7882_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s10456-022-09835-8","volume":"25","author":"D Sun","year":"2022","unstructured":"Sun D, et al. Molecular mechanisms of coronary microvascular endothelial dysfunction in diabetes mellitus: focus on mitochondrial quality surveillance. Angiogenesis. 2022;25(3):307\u201329.","journal-title":"Angiogenesis"},{"issue":"7","key":"7882_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41569-024-01115-w","volume":"22","author":"AW Khan","year":"2025","unstructured":"Khan AW, Jandeleit-Dahm KAM. Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches. Nat Rev Cardiol. 2025;22(7):482\u201396.","journal-title":"Nat Rev Cardiol"},{"issue":"19","key":"7882_CR6","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","volume":"287","author":"JA Beckman","year":"2002","unstructured":"Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570\u201381.","journal-title":"JAMA"},{"issue":"12","key":"7882_CR7","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","volume":"108","author":"MA Creager","year":"2003","unstructured":"Creager MA, et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527\u201332.","journal-title":"Circulation"},{"issue":"8","key":"7882_CR8","doi-asserted-by":"publisher","first-page":"e1671","DOI":"10.1210\/clinem\/dgae013","volume":"109","author":"R Muniyappa","year":"2024","unstructured":"Muniyappa R. Vascular Insulin Resistance and Free Fatty Acids: The Micro-Macro Circulation Nexus. J Clin Endocrinol Metab. 2024;109(8):e1671\u20132.","journal-title":"J Clin Endocrinol Metab"},{"key":"7882_CR9","doi-asserted-by":"publisher","first-page":"154766","DOI":"10.1016\/j.metabol.2021.154766","volume":"119","author":"MA Hill","year":"2021","unstructured":"Hill MA, et al. Insulin resistance, cardiovascular stiffening and cardiovascular disease. Metabolism. 2021;119:154766.","journal-title":"Metabolism"},{"issue":"1","key":"7882_CR10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1161\/01.CIR.102.1.42","volume":"102","author":"A Festa","year":"2000","unstructured":"Festa A, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000;102(1):42\u20137.","journal-title":"Circulation"},{"issue":"6","key":"7882_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s11892-014-0492-2","volume":"14","author":"RB Sharma","year":"2014","unstructured":"Sharma RB, Alonso LC. Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well? Curr Diab Rep. 2014;14(6):492.","journal-title":"Curr Diab Rep"},{"key":"7882_CR12","doi-asserted-by":"crossref","unstructured":"Sugiyama T, Yamamoto E, Bryniarski K, et al. Coronary Plaque Characteristics in Patients With Diabetes Mellitus Who Presented With Acute Coronary Syndromes. J Am Heart Assoc. 2018;7(14):e009245.","DOI":"10.1161\/JAHA.118.009245"},{"issue":"1","key":"7882_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12933-017-0635-2","volume":"16","author":"A Milzi","year":"2017","unstructured":"Milzi A, et al. Type 2 diabetes mellitus is associated with a lower fibrous cap thickness but has no impact on calcification morphology: an intracoronary optical coherence tomography study. Cardiovasc Diabetol. 2017;16(1):152.","journal-title":"Cardiovasc Diabetol"},{"key":"7882_CR14","doi-asserted-by":"publisher","first-page":"101236","DOI":"10.1016\/j.molmet.2021.101236","volume":"52","author":"J Fu","year":"2021","unstructured":"Fu J, et al. Insulin\u2019s actions on vascular tissues: Physiological effects and pathophysiological contributions to vascular complications of diabetes. Mol Metab. 2021;52:101236.","journal-title":"Mol Metab"},{"issue":"6","key":"7882_CR15","doi-asserted-by":"publisher","first-page":"H1218","DOI":"10.1152\/ajpheart.00826.2024","volume":"328","author":"WB Horton","year":"2025","unstructured":"Horton WB, et al. Metabolic and vascular insulin resistance: partners in the pathogenesis of cardiovascular disease in diabetes. Am J Physiol Heart Circ Physiol. 2025;328(6):H1218\u201336.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"7882_CR16","doi-asserted-by":"publisher","first-page":"E629","DOI":"10.1152\/ajpendo.00247.2020","volume":"319","author":"R Muniyappa","year":"2020","unstructured":"Muniyappa R, et al. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling. Am J Physiol Endocrinol Metab. 2020;319(3):E629\u201346.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"7882_CR17","doi-asserted-by":"publisher","first-page":"1149239","DOI":"10.3389\/fendo.2023.1149239","volume":"14","author":"X Zhao","year":"2023","unstructured":"Zhao X, et al. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol (Lausanne). 2023;14:1149239.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"16","key":"7882_CR18","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvae193","volume":"120","author":"Q Li","year":"2024","unstructured":"Li Q, et al. Insulin receptors in vascular smooth muscle cells regulate plaque stability of atherosclerosis. Cardiovasc Res. 2024;120(16):2017\u201330.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"7882_CR19","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1291\/hypres.19.SupplementI_S47","volume":"19","author":"T Imaizumi","year":"1996","unstructured":"Imaizumi T. Effects of intra-arterial infusion of insulin on control of forearm vascular resistance in normotensive and hypertensive subjects. Hypertens Res. 1996;19(Suppl 1):S47\u201350.","journal-title":"Hypertens Res"},{"issue":"5","key":"7882_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1254\/fpj.115.287","volume":"115","author":"H Kawasaki","year":"2000","unstructured":"Kawasaki H, Kuroda S, Mimaki Y. [Vascular effects of insulin]. Nihon Yakurigaku Zasshi. 2000;115(5):287\u201394.","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"10","key":"7882_CR21","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1016\/j.immuni.2025.09.011","volume":"58","author":"MY Donath","year":"2025","unstructured":"Donath MY, Drucker DJ. Obesity, diabetes, and inflammation: Pathophysiology and clinical implications. Immunity. 2025;58(10):2373\u201382.","journal-title":"Immunity"},{"issue":"2","key":"7882_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nm.2279","volume":"17","author":"B Vandanmagsar","year":"2011","unstructured":"Vandanmagsar B, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17(2):179\u201388.","journal-title":"Nat Med"},{"key":"7882_CR23","doi-asserted-by":"crossref","unstructured":"Guria S, et al. Adipose tissue macrophages and their role in obesity-associated insulin resistance: an overview of the complex dynamics at play. Biosci Rep. 2023;43(3):BSR20220200.","DOI":"10.1042\/BSR20220200"},{"issue":"7903","key":"7882_CR24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/s41586-022-04518-2","volume":"603","author":"MP Emont","year":"2022","unstructured":"Emont MP, et al. A single-cell atlas of human and mouse white adipose tissue. Nature. 2022;603(7903):926\u201333.","journal-title":"Nature"},{"key":"7882_CR25","doi-asserted-by":"crossref","unstructured":"Napoli G, Pergola V, Basile P, et al. Epicardial and Pericoronary Adipose Tissue, Coronary Inflammation, and Acute Coronary Syndromes. J Clin Med. 2023;12(23):7212.","DOI":"10.3390\/jcm12237212"},{"key":"7882_CR26","doi-asserted-by":"publisher","first-page":"111229","DOI":"10.1016\/j.cellsig.2024.111229","volume":"120","author":"K Yan","year":"2024","unstructured":"Yan K. Recent advances in the effect of adipose tissue inflammation on insulin resistance. Cell Signal. 2024;120:111229.","journal-title":"Cell Signal"},{"key":"7882_CR27","doi-asserted-by":"crossref","unstructured":"Niculescu R, Stoian A, Arb\u0103na\u0219i EM, et al. The Dual Role of Perivascular Adipose Tissue in Vascular Homeostasis and Atherogenesis: From Physiology to Pathological Implications. Int J Mol Sci. 2025;26(17):8320.","DOI":"10.3390\/ijms26178320"},{"issue":"12","key":"7882_CR28","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"26","key":"7882_CR29","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497\u2013505.","journal-title":"N Engl J Med"},{"issue":"19","key":"7882_CR30","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838\u201347.","journal-title":"N Engl J Med"},{"issue":"10289","key":"7882_CR31","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397(10289):2060\u20139.","journal-title":"Lancet"},{"key":"7882_CR32","doi-asserted-by":"crossref","unstructured":"Huang S, et al. ALKBH5 regulates inflammation and pyroptosis of coronary heart disease by targeting SPEN in a YTHDF1-Mediated Manner. Cardiovasc Drugs Ther. 2025.","DOI":"10.1007\/s10557-025-07746-6"},{"key":"7882_CR33","doi-asserted-by":"crossref","unstructured":"Song XF, et al. The Relationship and mechanism of CD27 with coronary atherosclerotic heart disease. Cardiovasc Drugs Ther. 2025.","DOI":"10.1007\/s10557-025-07740-y"},{"issue":"5","key":"7882_CR34","doi-asserted-by":"publisher","first-page":"H2023","DOI":"10.1152\/ajpheart.01283.2006","volume":"292","author":"DX Zhang","year":"2007","unstructured":"Zhang DX, Gutterman DD. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol. 2007;292(5):H2023\u201331.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"7882_CR35","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.bbrc.2005.10.053","volume":"338","author":"K Perez-de-Arce","year":"2005","unstructured":"Perez-de-Arce K, Foncea R, Leighton F. Reactive oxygen species mediates homocysteine-induced mitochondrial biogenesis in human endothelial cells: modulation by antioxidants. Biochem Biophys Res Commun. 2005;338(2):1103\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"7882_CR36","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12933-017-0531-9","volume":"16","author":"X Ren","year":"2017","unstructured":"Ren X, et al. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16(1):52.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"7882_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tcm.2013.12.001","volume":"24","author":"Y Higashi","year":"2014","unstructured":"Higashi Y, et al. Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications. Trends Cardiovasc Med. 2014;24(4):165\u20139.","journal-title":"Trends Cardiovasc Med"},{"issue":"8","key":"7882_CR38","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s12276-023-01043-8","volume":"55","author":"J Son","year":"2023","unstructured":"Son J, Accili D. Reversing pancreatic \u03b2-cell dedifferentiation in the treatment of type 2 diabetes. Exp Mol Med. 2023;55(8):1652\u20138.","journal-title":"Exp Mol Med"},{"issue":"6","key":"7882_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3892\/etm.2020.9396","volume":"20","author":"W Sha","year":"2020","unstructured":"Sha W, Hu F, Bu S. Mitochondrial dysfunction and pancreatic islet \u03b2-cell failure (Review). Exp Ther Med. 2020;20(6):266.","journal-title":"Exp Ther Med"},{"issue":"13\u201315","key":"7882_CR40","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1089\/ars.2023.0006","volume":"38","author":"T M\u00fcnzel","year":"2023","unstructured":"M\u00fcnzel T, Daiber A. Vascular Redox Signaling, Endothelial Nitric Oxide Synthase Uncoupling, and Endothelial Dysfunction in the Setting of Transportation Noise Exposure or Chronic Treatment with Organic Nitrates. Antioxid Redox Signal. 2023;38(13\u201315):1001\u201321.","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"7882_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/s41392-024-01839-8","volume":"9","author":"Y Zong","year":"2024","unstructured":"Zong Y, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9(1):124.","journal-title":"Signal Transduct Target Ther"},{"key":"7882_CR42","doi-asserted-by":"publisher","first-page":"106569","DOI":"10.1016\/j.biocel.2024.106569","volume":"170","author":"X Fang","year":"2024","unstructured":"Fang X, et al. Mitochondrial regulation of diabetic endothelial dysfunction: Pathophysiological links. Int J Biochem Cell Biol. 2024;170:106569.","journal-title":"Int J Biochem Cell Biol"},{"issue":"6","key":"7882_CR43","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10557-024-07639-0","volume":"39","author":"B Wang","year":"2025","unstructured":"Wang B, et al. AGE-RAGE Axis and Cardiovascular Diseases: Pathophysiologic Mechanisms and Prospects for Clinical Applications. Cardiovasc Drugs Ther. 2025;39(6):1489\u2013506.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"7882_CR44","doi-asserted-by":"publisher","first-page":"S285","DOI":"10.2337\/dc11-s239","volume":"34","author":"A Avogaro","year":"2011","unstructured":"Avogaro A, et al. Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care. 2011;34(2):S285\u201390.","journal-title":"Diabetes Care"},{"issue":"1","key":"7882_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11154-012-9229-1","volume":"14","author":"R Muniyappa","year":"2013","unstructured":"Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5\u201312.","journal-title":"Rev Endocr Metab Disord"},{"issue":"11","key":"7882_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.4330\/wjc.v2.i11.377","volume":"2","author":"A Picchi","year":"2010","unstructured":"Picchi A, et al. Coronary microvascular dysfunction in diabetes mellitus: A review. World J Cardiol. 2010;2(11):377\u201390.","journal-title":"World J Cardiol"},{"issue":"20","key":"7882_CR47","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1161\/CIRCULATIONAHA.111.050427","volume":"124","author":"VL Murthy","year":"2011","unstructured":"Murthy VL, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124(20):2215\u201324.","journal-title":"Circulation"},{"issue":"5","key":"7882_CR48","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1093\/ehjci\/jead023","volume":"24","author":"A Aljizeeri","year":"2023","unstructured":"Aljizeeri A, et al. Incremental prognostic value of positron emission tomography-derived myocardial flow reserve in patients with and without diabetes mellitus. Eur Heart J Cardiovasc Imaging. 2023;24(5):563\u201371.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"7882_CR49","doi-asserted-by":"publisher","first-page":"p6850187","DOI":"10.1155\/2020\/6850187","volume":"2020","author":"Z Bao","year":"2020","unstructured":"Bao Z, et al. Advanced Glycation End Products Induce Vascular Smooth Muscle Cell-Derived Foam Cell Formation and Transdifferentiate to a Macrophage-Like State. Mediators Inflamm. 2020;2020:p6850187.","journal-title":"Mediators Inflamm"},{"issue":"2","key":"7882_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jcct.2024.12.083","volume":"19","author":"ZM Gebert","year":"2025","unstructured":"Gebert ZM, et al. Impact of diabetes mellitus on coronary artery plaque characteristics and outcomes in the SCOT-HEART trial. J Cardiovasc Comput Tomogr. 2025;19(2):208\u201314.","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"11","key":"7882_CR51","doi-asserted-by":"publisher","first-page":"e707","DOI":"10.4244\/EIJ-D-23-00628","volume":"20","author":"D Del Val","year":"2024","unstructured":"Del Val D, et al. Vulnerable plaque features and adverse events in patients with diabetes mellitus: a post hoc analysis of the COMBINE OCT-FFR trial. EuroIntervention. 2024;20(11):e707\u201317.","journal-title":"EuroIntervention"},{"issue":"1","key":"7882_CR52","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12933-023-01844-1","volume":"22","author":"TM Hommels","year":"2023","unstructured":"Hommels TM, et al. Exploring new insights in coronary lesion assessment and treatment in patients with diabetes mellitus: the impact of optical coherence tomography. Cardiovasc Diabetol. 2023;22(1):123.","journal-title":"Cardiovasc Diabetol"},{"key":"7882_CR53","doi-asserted-by":"crossref","unstructured":"Li X, Weber NC, Cohn DM, et al. Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. J Clin Med. 2021;10(11):2419.","DOI":"10.3390\/jcm10112419"},{"key":"7882_CR54","doi-asserted-by":"publisher","first-page":"112772","DOI":"10.1016\/j.biopha.2022.112772","volume":"148","author":"EE Babes","year":"2022","unstructured":"Babes EE, et al. Acute coronary syndromes in diabetic patients, outcome, revascularization, and antithrombotic therapy. Biomed Pharmacother. 2022;148:112772.","journal-title":"Biomed Pharmacother"},{"key":"7882_CR55","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, et al. Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines. 2022;10(9):2274.","DOI":"10.3390\/biomedicines10092274"},{"issue":"1","key":"7882_CR56","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","volume":"42","author":"WB Horton","year":"2021","unstructured":"Horton WB, Barrett EJ. Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease. Endocr Rev. 2021;42(1):29\u201355.","journal-title":"Endocr Rev"},{"key":"7882_CR57","doi-asserted-by":"crossref","unstructured":"Abudureyimu M, Luo X, Wang X, et al. Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics. J Mol Cell Biol. 2022;14(5):mjac028.","DOI":"10.1093\/jmcb\/mjac028"},{"key":"7882_CR58","doi-asserted-by":"crossref","unstructured":"Li Z, Shi Y, Xia Y, et al. Disparate Clinical Characteristics and Prognosis of HFpEF versus HFrEF Phenotype of Diabetic Cardiomyopathy. J Clin Med. 2023;12(4):1565.","DOI":"10.3390\/jcm12041565"},{"issue":"4","key":"7882_CR59","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jacc.2006.05.039","volume":"48","author":"A Poli","year":"2006","unstructured":"Poli A, Pujia A. Pleiotropic effects of statins and early benefit in the PROVE IT-TIMI-22 study. J Am Coll Cardiol. 2006;48(4):852. author reply 852-3.","journal-title":"J Am Coll Cardiol"},{"key":"7882_CR60","doi-asserted-by":"crossref","unstructured":"Peacock EJ. The Statin floor effect: a mechanistic framework for residual cardiovascular risk. Cardiovasc Drugs Ther. 2026.","DOI":"10.20944\/preprints202510.0398.v1"},{"issue":"9386","key":"7882_CR61","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","volume":"362","author":"KM Fox","year":"2003","unstructured":"Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362(9386):782\u20138.","journal-title":"Lancet"},{"issue":"10204","key":"7882_CR62","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S0140-6736(19)31887-2","volume":"394","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169\u201380.","journal-title":"Lancet"},{"issue":"14","key":"7882_CR63","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309\u201320.","journal-title":"N Engl J Med"},{"key":"7882_CR64","doi-asserted-by":"crossref","unstructured":"Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight\/Obesity: Results From the Look AHEAD Study. Diabetes Care. 2022;45(5):1252\u20139.","DOI":"10.2337\/dc21-1805"},{"issue":"2","key":"7882_CR65","doi-asserted-by":"publisher","first-page":"e240219","DOI":"10.1001\/jamanetworkopen.2024.0219","volume":"7","author":"Z Huang","year":"2024","unstructured":"Huang Z, et al. Physical Activity and Weight Loss Among Adults With Type 2 Diabetes and Overweight or Obesity: A Post Hoc Analysis of the Look AHEAD Trial. JAMA Netw Open. 2024;7(2):e240219.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"7882_CR66","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMc1600827","volume":"374","author":"PA Sarafidis","year":"2016","unstructured":"Sarafidis PA, Tsapas A. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2016;374(11):1092.","journal-title":"N Engl J Med"},{"issue":"15","key":"7882_CR67","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"4","key":"7882_CR68","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"24","key":"7882_CR69","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"1","key":"7882_CR70","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s10557-025-07670-9","volume":"40","author":"X Zhang","year":"2026","unstructured":"Zhang X, et al. Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. Cardiovasc Drugs Ther. 2026;40(1):287\u2013301.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"22","key":"7882_CR71","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"7882_CR72","doi-asserted-by":"publisher","first-page":"E291","DOI":"10.1152\/ajpendo.00143.2023","volume":"325","author":"KL Whytock","year":"2023","unstructured":"Whytock KL, et al. Comprehensive interrogation of human skeletal muscle reveals a dissociation between insulin resistance and mitochondrial capacity. Am J Physiol Endocrinol Metab. 2023;325(4):E291\u2013302.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"7882_CR73","doi-asserted-by":"publisher","first-page":"H797","DOI":"10.1152\/ajpheart.2002.282.3.H797","volume":"282","author":"A Shihabi","year":"2002","unstructured":"Shihabi A, et al. Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls. Am J Physiol Heart Circ Physiol. 2002;282(3):H797\u2013802.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"10","key":"7882_CR74","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00259-006-0069-7","volume":"33","author":"TH Schindler","year":"2006","unstructured":"Schindler TH, et al. PET-measured heterogeneity in longitudinal myocardial blood flow in response to sympathetic and pharmacologic stress as a non-invasive probe of epicardial vasomotor dysfunction. Eur J Nucl Med Mol Imaging. 2006;33(10):1140\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"7882_CR75","doi-asserted-by":"publisher","first-page":"e021976","DOI":"10.1161\/JAHA.121.021976","volume":"10","author":"AM Flores","year":"2021","unstructured":"Flores AM, et al. Unsupervised Learning for Automated Detection of Coronary Artery Disease Subgroups. J Am Heart Assoc. 2021;10(23):e021976.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"7882_CR76","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/ehjci\/jead028","volume":"24","author":"TH Schindler","year":"2023","unstructured":"Schindler TH, Valenta I. Coronary microvascular dysfunction and prognostication in diabetes mellitus. Eur Heart J Cardiovasc Imaging. 2023;24(5):572\u20133.","journal-title":"Eur Heart J Cardiovasc Imaging"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-026-07882-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-026-07882-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:27:55Z","timestamp":1789532875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-026-07882-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["7882"],"URL":"https:\/\/doi.org\/10.1007\/s10557-026-07882-7","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}